Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 5 , Pages 406-418 , September 2009

Defining and labeling disease-modifying treatments for Alzheimer's disease

References 

  1. Doody RS. We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development. Alzheimers & Dementia. 2008;4:S21–S25
  2. Knopman D. Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying. Alzheimers & Dementia. 2006;2:147–149
  3. Mani RB. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Stat Med. 2004;23:305–314
  4. Sampaio C. Alzheimer disease: disease modifying trials: where are we? where do we need to go? a reflective paper. J Nutr Health Aging. 2006;10:113–115
  5. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57:481–488Erratum in: Neurology 2001;57:1942
  6. DeCarli C, Frisoni GB, Clark CM, Harvey D, Grundman M, Petersen RC, et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol. 2007;64:108–115
  7. Vellas B, Andrieu S, Sampaio C, Wilcock G. European Task Force group. Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurol. 2007;6:56–62
  8. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004;363:2105–2115
  9. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216–223
  10. Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007;69:878–885
  11. Sparks DL, Lemieux SK, Haut MW, Baxter LC, Johnson SC, Sparks LM, et al. Hippocampal volume change in the Alzheimer disease cholesterol-lowering treatment trial. Cleve Clin J Med. 2008;75:S87–S93
  12. Szekely CA, Green RC, Breitner JC, Østbye T, Beiser AS, Corrada MM, et al. No advantage of Abeta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology. 2008;70:2291–2298
  13. Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007;69:1622–1634
  14. Cummings JL. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimers & Dementia. 2006;2:263–271
  15. Leber P. Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord. 1996;10:31–35
  16. Leber P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord. 1997;11:S10–S21
  17. Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S. Galantamine provides sustained benefits in patients with “advanced moderate” Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord. 2003;15:79–87
  18. Horton S, Gutin A, Hendrix S. A mathematical comparison of a “randomized withdrawal” clinical trial design and a parallel groups design to demonstrate disease modification in Alzheimer's disease (AD). Alzheimers & Dementia. 2007;3:S161
  19. Siderowf A, Stern M. Clinical trials with rasagiline: evidence for short-term and long-term effects. Neurology. 2006;66:S80–S88
  20. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561–566
  21. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–2388
  22. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: the Alzheimer's Disease Cooperative Study. N Engl J Med. 1997;336:1216–1222
  23. Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G. European Task Force Group. Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol. 2008;7:436–450
  24. Leber P. Draft guidelines for the clinical evaluation of antidementia drugs. Rockville, MD: Food and Drug Administration; 1990;
  25. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry. 2003;11:131–145
  26. Feigin A. Evidence from biomarkers and surrogate endpoints. NeuroRx. 2004;1:323–330
  27. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs?. JAMA. 1999;282:790–795
  28. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx. 2004;1:189–195
  29. Lovestone S. Biomarkers in Alzheimer's disease. J Nutr Health Aging. 2006;10:118–122
  30. Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, et al. Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. Neuroimage. 2008;43:59–68
  31. Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells JL, et al. Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain. 2008;131:2443–2454
  32. Bobinski M, de Leon MJ, Wegiel J, Desanti S, Convit A, Saint Louis LA, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience. 2000;95:721–725
  33. Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przybelski SA, Weigand SD, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology. 2008;71:743–749
  34. Ridha BH, Anderson VM, Barnes J, Boyes RG, Price SL, Rossor MN, et al. Volumetric MRI and cognitive measures in Alzheimer disease: comparison of markers of progression. J Neurol. 2008;255:567–574
  35. Jagust W. Molecular neuroimaging in Alzheimer's disease. NeuroRx. 2004;1:206–212
  36. Mega MS, Cummings JL, O'Connor SM, Dinov ID, Reback E, Felix J, et al. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14:63–68
  37. Mega MS, Dinov ID, Porter V, Chow G, Reback E, Davoodi P, et al. Metabolic patterns associated with the clinical response to galantamine therapy. Arch Neurol. 2005;62:721–728
  38. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630–1645
  39. Csernansky JG, Miller JP, McKeel D, Morris JC. Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 2002;16:144–149
  40. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512–519
  41. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553–1562
  42. Grundman M, Black RS. O3-04-05: clinical trials of bapineuzumab, a beta-amyloid-targeted immunotherapy in patients with mild to moderate Alzheimer's disease. Alzheimers & Dementia. 2008;4:T166
  43. Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia. 2008;46:1688–1697
  44. Stomrud E, Hansson O, Blennow K, Minthon L, Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord. 2007;24:118–124
  45. Apostolova LG, Mosconi L, Thompson PM, Green AE, Hwang KS, Ramirez A, et al. Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. Neurobiol Aging. 2008;Sept 24 [Epub ahead of print]
  46. Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, et al. The role of biomarkers in clinical trials for Alzheimer's disease. Alzheimer Dis Assoc Disord. 2006;20:6–15
  47. Jack CR, Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397–1403
  48. Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol. 2006;60:145–147
  49. Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685–691
  50. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers & Dementia. 2005;1:55–66
  51. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921–923
  52. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61:661–666
  53. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 2004;63:1187–1192
  54. Cupples LA, Farrer LA, Sadovnick AD, Relkin N, Whitehouse P, Green RC. Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med. 2004;6:192–196
  55. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21:49–55
  56. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, et al. Stroke and the risk of Alzheimer disease. Arch Neurol. 2003;60:1707–1712
  57. Borstein Graves A, Mortimer JA, Bowen JD, McCormick WC, McCurry SM, Schellenberg GD, et al. Head circumference and incident Alzheimer's disease. Neurology. 2001;57:1453–1460
  58. Schofield PW, Logroscino G, Andrews HF, Albert S, Stern Y. An association between head circumference and Alzheimer's disease in a population-based study of aging and dementia. Neurology. 1997;49:30–37
  59. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke. 2002;33:2351–2356
  60. Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Manjon M, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology. 2003;61:199–205
  61. Shobab LA, Hsiung GY, Feldman HH. Cholesterol in Alzheimer's disease. Lancet Neurol. 2005;4:841–852
  62. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006;5:735–741
  63. ADAPT Research GroupMartin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008;65:896–905

PII: S1552-5260(09)00022-3

doi: 10.1016/j.jalz.2008.12.003

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 5 , Pages 406-418 , September 2009

Article Tools

* Image Usage & Resolution